期刊文献+

基因芯片筛选结肠癌伊立替康耐药相关基因 被引量:4

Analysis of Gene Expression Patterns in an Irinotecan-resistance Colon Cancer Cell by cDNA Microarray
原文传递
导出
摘要 目的应用基因芯片技术进行结肠癌伊立替康耐药相关基因表达谱差异分析,探讨伊立替康结肠癌耐药发生机制。方法分别抽提人结肠癌细胞系SW480及其伊立替康耐药细胞系SW480/CPT总RNA,逆转录合成相应以Cy3标记的cRNA做探针,在Agilent基因芯片上杂交,Axon4000B扫描仪扫描芯片荧光信号图像,Genepix3.0图像软件对扫描图像进行数字化处理和分析。利用RT-PCR对筛选出的部分差异表达基因进行验证。结果筛选出差异表达基因1598个,其中基因表达上调911个,基因表达下调687个。谷胱甘肽S转移酶同工酶(GSTA)家族GSTA1、GSTA2、GSTA3、GSTA5明显上调,锌指蛋白(ZNF)家族多个成员也有显著差异表达。结论基因芯片结果提示,GSTA与ZNF基因可能在介导伊立替康耐药过程中起着重要的调控作用。 Objective To study the mechanism of irinotecan-resistant colon cancer by analyzing the differential gene expression patterns with cDNA microarray.Methods Total RNA was purified from irinotecan-sensitive colonic cancer cell line,SW480 and its irinotecan-resistance cell line,SW480/CPT.The cRNA retro-transcribed from RNA were labeled with Cy3 fluorescence as probes.The probes were hybridized with Agilent gene chips and the fluorescence images of the chips were obtained with Axon 4000B scanner as well as analyzed with Genepix 3.0 software.The microarray results were confirmed by reverse transcription-polymerase chain reaction.Results Of the 1598 genes with altered expressions,there were 911 up-regulated genes and 687 down-regulated genes.Glutathione S-Transferase(GST) isoenzyme family GSTA such as GSTA1,GSTA2,GSTA3 and GSTA5 were significantly up-regulated.The expression levels of many Zinc finger protein family members(ZNF) were also differentially regulated.Conclusion GSTA and ZNF subunit genes might play an important regulation role in the irinotecan resistance of colon cancer.
出处 《四川大学学报(医学版)》 CAS CSCD 北大核心 2011年第1期15-18,36,共5页 Journal of Sichuan University(Medical Sciences)
基金 国家自然科学基金(批准号30901719 30971519)资助
关键词 基因芯片 伊立替康 耐药 结肠癌 基因表达 cDNA microarray Irinotecan Drug resistance Colon cancer Gene expression
  • 相关文献

参考文献12

  • 1Tourniqand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced eoloreetal cancer: a randomized GERCOR study. J Clin Oneol, 2004 ; 22 (2) : 229- 237.
  • 2Kihara C, Tsunoda T, Tanaka T, et al. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene expression profiles. Cancer Rest 2001~61(17) :6474 6479.
  • 3Tang H, Liu YJ, Liu M, et al. Establishment and gene analysis of an oxaliplatin-resistant colon cancer cell line THC8307/LOHP. Anticancer Drugs,2007;18(6) :633-639.
  • 4Minderman H, Conroy JM, O'Loughlin KL, et al. In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther, 2005 , 4 (6) : 885-900.
  • 5Bhonde MR, Hanski ML, Budczies J, et al. DNA damageinduced expression of p53 suppresses mitotic checkpoint kinase hMpsl :the lack of this suppression in p53MUT cells contributes to apoptosis. J Biol Chem,2006,281(13):8675-8685.
  • 6Chun JH, Kim HK, Kim E, et al. Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer. Cancer Res,2004;64(14):4703-4706.
  • 7Britton RA, Green JA, Warranties HM. Cellular gluytothione (GSH) and glutathione S-transferase (GST) aetivity in human ovarian tumor biopsies following exposure to alkylating agents. In J Radiat Oncol Biolphys,1992,24(3) :527-531.
  • 8Sharma A, Patrick B, Li J, et al. Glutathione S-transferases as antioxidant enzymes: small cell lung cancer (H69) cells transfected with hGSTA1 resist doxorubicin-induced apoptosis. Arch Bioehem Biophys,2006,452(2):165-173.
  • 9Smitherman PK, Townsend AJ, Kute TE, et al. Role of multiclrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxifieation: MRP2 potentiates glutathione S- transferase Al-1-mediated resistance to chlorambucil eytotoxicity. J Pharmacol Exp Ther, 2004 , 308 (1) : 260-267.
  • 10Fotouhi-Ardakani N, Batist G. Genomic cloning and characterization of the rat glutathione S-transferase-A3-subunit gene. Biochem J,1999,339(Pt 3):685-693.

同被引文献32

  • 1孙军,林矫矫,程国锋,李浩,石耀军,陆珂,蔡幼民,江洪波.利用基因表达谱芯片研究东方田鼠和小鼠感染日本血吸虫前后基因的差异性表达[J].北京大学学报(自然科学版),2004,40(4):532-537. 被引量:17
  • 2李东娅,章晓梅,唐莉.S100蛋白与相关疾病[J].医学研究杂志,2007,36(9):95-97. 被引量:8
  • 3Bartel DP. MicroRNAs: target recognition and regulatory functions[J]. Cell,2009,136(2) :215-233.
  • 4Bushati N, Cohen SM. MicroRNA functions[ J]. Annu Rev Cell DevBiol,2007,23 :175-205.
  • 5Croce CM. Causes and consequences of microRNA dysregulation incancer[ J]. Nat Rev Genet,2009,10( 10) :704-714.
  • 6Igarashi M,Nagata A, Jinno S,et al. Weel ( + )-like gene in humancells[j]. Nature,1991,353(6339) :80-83.
  • 7Wang Y, Decker SJ , Sebolt-Leopold J. Knockdown of Chkl, Weeland Mytl by RNA interference abrogates G2 checkpoint and inducesapoptosis[ J]. Cancer Biol Ther,2004,3(3) :305-313.
  • 8Ghiasi N,Habibagahi M,Rosli R,et al. Tumour suppressive effects ofWEE1 gene silencing in breast cancer cells [ J ]. Asian Pac J CancerPrev, 2013 ,14 (11) : 6605 -6611.
  • 9Pouliot LM, Chen YG, Bai J, et al. Cisplatin sensitivity mediated byWEE1 and CHK1 is mediated by miR-155 and the miR-15 family[J]. Cancer Res,2012,72(22) :5945-5955.
  • 10Dixon H,Norbury CJ. Therapeutic exploitation of checkpoint defectsin cancer cells lacking p53 function[ J]. Cell Cycle,2002 ,1(6) :362-368.

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部